Home>Topics>Stocks>Celgene Corporation

Celgene Corporation CELG

  1. All
  2. Commentary
  3. Fund Reports
  4. ETF Reports
  5. Headlines
    1. Concert Pharma begins clinical development of anti-inflammatory drug candidate from Celgene collaboration

      Headlines

      Wed, 17 Sep 2014

      and pharmacokinetics of its investigational compound CTP-730. The trial should be completed in 2015. CTP-730 is the initial product candidate produced from Concert's collaboration with Celgene ( CELG +0.6% ). Post your comment!

    2. Cramer's Mad Money - The World Is Slowing, And Slowing Fast (9/16/14)

      Headlines

      Wed, 17 Sep 2014

      By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday September 16. Note to Fed: The World Is Slowing, And Slowing Fast The world is slowing, and slowing fast. China has now become a huge negative, Alibaba aside. The iPhone in China

    3. Cramer's Mad Money - Angie's List For Self-Improvement (9/15/14)

      Headlines

      Tue, 16 Sep 2014

      By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday September 15. Angie's List (NASDAQ: ANGI ) . Other stock mentioned: Yelp (NYSE: YELP ) Angie's List ( ANGI ) is a website that specializes in reviews and is one of the "most hated

    4. Celgene Looks Unstoppable

      Headlines

      Mon, 15 Sep 2014

      By Ray Merola : Since mid-2012, Celgene Corporation (NASDAQ: CELG ) stock has tripled. Nonetheless, I submit the shares still represent a highly positive, asymmetric risk-reward proposal

    5. Celgene's Management Presents at Morgan Stanley Global Healthcare Conference (Transcript)

      Headlines

      Tue, 9 Sep 2014

      By SA Transcripts : Celgene Corporation (NASDAQ: CELG ) Morgan Stanley Healthcare Conference Call September 9, 2014 12:55 PM ET Executives Scott A. Smith – President, Global Inflammation

    6. Determining Celgene's Fair Value

      Headlines

      Wed, 3 Sep 2014

      capitalization of $76 billion, Celgene Corporation (NASDAQ: CELG ) is one of the biggest biotech ..... accounts for 60% of revenue. CELG Revenue (NYSE: TTM ) data by ..... years. Celgene's fundamentals CELG Return on Equity ( TTM ) data

    7. Cramer's Mad Money - Fascinating Schisms (9/2/14)

      Headlines

      Wed, 3 Sep 2014

      NYSE: PRGO ), Mallinckrodt (NYSE: MNK ), Regeneron (NASDAQ: REGN ), Gilead (NASDAQ: GILD ) and Celgene (NASDAQ: CELG ), Union Pacific (NYSE: UNP ), Norfolk Southern (NYSE: NSC ), Automatic Data Processing (NASDAQ: ADP ), Waste Management

    8. XBI SPDR S&P Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Tue, 2 Sep 2014

      the broader market over the past five years. Some firms held in this ETF, such as Regeneron REGN, Biogen Idec BIIB, Celgene CELG , Gilead GILD, and Amgen AMGN, have led the rally, benefiting from key drug approvals, strong sales of already-approved

    9. FBT First Trust NYSE Arca Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Tue, 2 Sep 2014

      outperformed the broader market over the past five years. Some firms held in this ETF, such as Regeneron REGN, Biogen BIIB, Celgene CELG , Gilead GILD, and Amgen AMGN, have led the rally, benefiting from key drug approvals, strong sales of already-approved

    10. IBB iShares Nasdaq Biotechnology ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Tue, 2 Sep 2014

      the broader market over the past five years. The firms at the top of this ETF, such as Regeneron REGN, Biogen BIIB, Celgene CELG , Gilead GILD, and Amgen AMGN, have led the rally, benefiting from key drug approvals, strong sales of already-approved

    « Prev12345Next »
    Content Partners